ReviewNature reviews. Cancer2003
Clinical development of gene therapy for colorectal cancer.
Review in Nature reviews. Cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review.Journal of translational medicine · 2011Pooled it
- Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer.Cancer science · 2017Trial
- Self-sufficient killing of malignant tumors by an engineered cancer-selective gene circuit.Cell reports. Medicine · 2026Article
- Advances in cancer nanovaccines: a focus on colorectal cancer.Nanomedicine (London, England) · 2025Review
- Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link.International journal of colorectal disease · 2024Review
- β-carboline derivative Z86 attenuates colorectal cancer cell proliferation and migration by directly targeting PI3K.Natural products and bioprospecting · 2024Article
- CRISPR/Cas9: a powerful tool in colorectal cancer research.Journal of experimental & clinical cancer research : CR · 2023Review
- Diatom-Based Nanomedicine for Colorectal Cancer Treatment: New Approaches for Old Challenges.Marine drugs · 2023Review
- LncRNA LINC01207 Could Positively Regulate the Development of Colorectal Cancer.Journal of oncology · 2023Article
- Article
- Downregulation of STK4 promotes colon cancer invasion/migration through blocking β-catenin degradation.Molecular oncology · 2020Article
- Article
- Combination of targeting CD24 and inhibiting autophagy suppresses the proliferation and enhances the apoptosis of colorectal cancer cells.Molecular medicine reports · 2019Article
- p53 positively regulates the expression of cancer stem cell marker CD133 in HCT116 colon cancer cells.Oncology letters · 2018Article
- A Universal Tumor-Specific Promoter for Cancer Gene Therapy.Doklady. Biochemistry and biophysics · 2018Article
- Up-regulation of microRNA-19b is associated with metastasis and predicts poor prognosis in patients with colorectal cancer.International journal of clinical and experimental pathology · 2018Article
- AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms.PloS one · 2017Article
- Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.Oncotarget · 2016Article
- Comparative profiling between primary colorectal carcinomas and metastases identifies heterogeneity on drug resistance.Oncotarget · 2016Article
- Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the second most common type of malignancy in Western nations. Improvements in surgical and radiotherapeutic techniques and the increased availability of new cytotoxic drugs have improved outcome, but 50% of patients still die from recurrent or metastatic disease. Several features of its natural history render CRC a good candidate for gene therapy. Techniques include gene replacement, virus-directed enzyme-prodrug therapy, immune manipulation and virotherapy, all of which have entered clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.